Immune Response Mechanisms in Haemophilia A

Abstract

Haemophilia A (HA) is an X-linked bleeding disorder caused by the deficiency or dysfunction of coagulation factor VIII (FVIII). Substitution therapy with recombinant or plasma-derived FVIII effectively restores haemostasis but carries the risk of eliciting FVIII-specific neutralizing antibodies known as inhibitors. Inhibitor formation reflects the absence of central immune tolerance, driven by complex interactions among antigen-presenting cells, B cells and CD4 T cell subsets. Recent studies highlight the essential roles of T cell polarization, costimulatory signalling and cytokine networks in shaping the immunogenic or tolerogenic outcome of FVIII exposure. This review summarizes mechanistic insights into how distinct CD4 T cell subpopulations, including Th1, Th2, Th17, follicular helper (Tfh), follicular regulatory (Tfr) and regulatory T cells (Tregs), influence inhibitor development in HA. Furthermore, it discusses emerging immunological concepts and cellular pathways that could be targeted to achieve durable tolerance towards FVIII, with emphasis on translational strategies that align mechanistic understanding with clinical need.

Keywords

haemophilia A - inhibitors - factor 8 - CD4 T cell subsets - regulatory T cells

Publication History

Received: 31 October 2025

Accepted: 17 November 2025

Article published online:
17 February 2026

• References

• 1 Schep SJ, Schutgens REG, Fischer K, Boes ML. Review of immune tolerance induction in hemophilia A. Blood Rev 2018; 32 (04) 326-338
• 2 Astermark J. FVIII inhibitors: pathogenesis and avoidance. Blood 2015; 125 (13) 2045-2051
• 3 Lacroix-Desmazes S, Voorberg J, Lillicrap D, Scott DW, Pratt KP. Tolerating factor VIII: recent progress. Front Immunol 2020; 10: 2991
• 4 Whelan SFJ, Hofbauer CJ, Horling FM. et al. Distinct characteristics of antibody responses against factor VIII in healthy individuals and in different cohorts of hemophilia A patients. Blood 2013; 121 (06) 1039-1048
• 5 Yousphi AS, Bakhtiar A, Cheema MA, Nasim S, Ullah W. Acquired hemophilia A: a rare but potentially fatal bleeding disorder. Cureus 2019; 11 (08) e5442
• 6 Hofbauer CJ, Whelan SFJ, Hirschler M. et al. Affinity of FVIII-specific antibodies reveals major differences between neutralizing and nonneutralizing antibodies in humans. Blood 2015; 125 (07) 1180-1188
• 7 Sun L, Su Y, Jiao A, Wang X, Zhang B. T cells in health and disease. Signal Transduct Target Ther 2023; 8 (01) 235
• 8 Singer ST, Addiego Jr JE, Reason DC, Lucas AH. T lymphocyte proliferative responses induced by recombinant factor VIII in hemophilia A patients with inhibitors. Thromb Haemost 1996; 76 (01) 17-22
• 9 Bray GL, Kroner BL, Arkin S. et al. Loss of high-responder inhibitors in patients with severe hemophilia A and human immunodeficiency virus type 1 infection: a report from the Multi-Center Hemophilia Cohort Study. Am J Hematol 1993; 42 (04) 375-379
• 10 Meunier S, Menier C, Marcon E, Lacroix-Desmazes S, Maillère B. CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells. Blood Adv 2017; 1 (21) 1842-1847
• 11 Qian J, Borovok M, Bi L, Kazazian Jr HH, Hoyer LW. Inhibitor antibody development and T cell response to human factor VIII in murine hemophilia A. Thromb Haemost 1999; 81 (02) 240-244
• 12 Waters B, Qadura M, Burnett E. et al. Anti-CD3 prevents factor VIII inhibitor development in hemophilia A mice by a regulatory CD4+CD25+-dependent mechanism and by shifting cytokine production to favor a Th1 response. Blood 2009; 113 (01) 193-203
• 13 Navarrete A, Dasgupta S, Delignat S. et al. Splenic marginal zone antigen-presenting cells are critical for the primary allo-immune response to therapeutic factor VIII in hemophilia A. J Thromb Haemost 2009; 7 (11) 1816-1823
• 14 Kaczmarek R, Piñeros AR, Patterson PE. et al. Factor VIII trafficking to CD4+ T cells shapes its immunogenicity and requires several types of antigen-presenting cells. Blood 2023; 142 (03) 290-305
• 15 Steinitz KN, van Helden PM, Binder B. et al. CD4+ T-cell epitopes associated with antibody responses after intravenously and subcutaneously applied human FVIII in humanized hemophilic E17 HLA-DRB1*1501 mice. Blood 2012; 119 (17) 4073-4082
• 16 Shah K, Al-Haidari A, Sun J, Kazi JU. T cell receptor (TCR) signaling in health and disease. Signal Transduct Target Ther 2021; 6 (01) 412
• 17 Rossi G, Sarkar J, Scandella D. Long-term induction of immune tolerance after blockade of CD40-CD40L interaction in a mouse model of hemophilia A. Blood 2001; 97 (09) 2750-2757
• 18 Pitner RA, Chao JL, Dahl NP. et al. Blunting specific T-dependent antibody responses with engineered “decoy” B cells. Mol Ther 2024; 32 (10) 3453-3469
• 19 Olatunde AC, Hale JS, Lamb TJ. Cytokine-skewed Tfh cells: functional consequences for B cell help. Trends Immunol 2021; 42 (06) 536-550
• 20 Mesin L, Ersching J, Victora GD. Germinal center B cell dynamics. Immunity 2016; 45 (03) 471-482
• 21 Reding MT, Lei S, Lei H, Green D, Gill J, Conti-Fine BM. Distribution of Th1- and Th2-induced anti-factor VIII IgG subclasses in congenital and acquired hemophilia patients. Thromb Haemost 2002; 88 (04) 568-575
• 22 Patel SR, Lundgren TS, Baldwin WH. et al. Neutralizing antibodies against factor VIII can occur through a non-germinal center pathway. Front Immunol 2022; 13: 880829
• 23 Ettinger RA, James EA, Kwok WW, Thompson AR, Pratt KP. Lineages of human T-cell clones, including T helper 17/T helper 1 cells, isolated at different stages of anti-factor VIII immune responses. Blood 2009; 114 (07) 1423-1428
• 24 Hu GL, Okita DK, Diethelm-Okita BM, Conti-Fine BM. Recognition of coagulation factor VIII by CD4+ T cells of healthy humans. J Thromb Haemost 2003; 1 (10) 2159-2166
• 25 Wu H, Reding M, Qian J. et al. Mechanism of the immune response to human factor VIII in murine hemophilia A. Thromb Haemost 2001; 85 (01) 125-133
• 26 Crotty S. T follicular helper cell biology: a decade of discovery and diseases. Immunity 2019; 50 (05) 1132-1148
• 27 Fan MN, Shen T, Konkle BA. et al. Exploration of biomarkers for inhibitor development in persons with hemophilia A. Res Pract Thromb Haemost 2025; 9 (04) 102877
• 28 Jing W, Chen J, Cai Y. et al. Induction of activated T follicular helper cells is critical for anti-FVIII inhibitor development in hemophilia A mice. Blood Adv 2019; 3 (20) 3099-3110
• 29 Zheng Q, Lin K, Zhang N, Shi Q, Wu Y, Chen Y. Anti-mCD20 in combination with α-mCXCL13 monoclonal antibody inhibits anti-FVIII antibody development in hemophilia A mice. Int Immunopharmacol 2024; 139: 112735
• 30 Miao CH, Harmeling BR, Ziegler SF. et al. CD4+FOXP3+ regulatory T cells confer long-term regulation of factor VIII-specific immune responses in plasmid-mediated gene therapy-treated hemophilia mice. Blood 2009; 114 (19) 4034-4044
• 31 Dikiy S, Rudensky AY. Principles of regulatory T cell function. Immunity 2023; 56 (02) 240-255
• 32 Menier C, Meunier S, Porcheddu V. et al. Frequency of natural regulatory T cells specific for factor VIII in the peripheral blood of healthy donors. Eur J Immunol 2024; 54 (04) e2350506
• 33 Becker-Gotot J, Meissner M, Kotov V. et al. Immune tolerance against infused FVIII in hemophilia A is mediated by PD-L1+ Tregs. J Clin Invest 2022; 132 (22) e159925
• 34 Kwon KC, Sherman A, Chang WJ. et al. Expression and assembly of largest foreign protein in chloroplasts: oral delivery of human FVIII made in lettuce chloroplasts robustly suppresses inhibitor formation in haemophilia A mice. Plant Biotechnol J 2018; 16 (06) 1148-1160
• 35 Sage PT, Sharpe AH. The multifaceted functions of follicular regulatory T cells. Curr Opin Immunol 2020; 67: 68-74
• 36 Jing W, Schroeder JA, Kumar S. et al. The T follicular helper/T follicular helper regulatory pathway in FVIII immune responses in mice. Blood 2025; 146 (08) 998-1010
• 37 Hausl C, Ahmad RU, Sasgary M. et al. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood 2005; 106 (10) 3415-3422
• 38 Qadura M, Othman M, Waters B. et al. Reduction of the immune response to factor VIII mediated through tolerogenic factor VIII presentation by immature dendritic cells. J Thromb Haemost 2008; 6 (12) 2095-2104
• 39 Antun A, Monahan PE, Manco-Johnson MJ. et al. Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study. J Thromb Haemost 2015; 13 (11) 1980-1988
• 40 Wang X, Terhorst C, Herzog RW. In vivo induction of regulatory T cells for immune tolerance in hemophilia. Cell Immunol 2016; 301: 18-29
• 41 Liu CL, Ye P, Lin J, Djukovic D, Miao CH. Long-term tolerance to factor VIII is achieved by administration of IL-2/IL-2mAb complexes and low dosages of factor VIII. J Thromb Haemost 2014; 12 (06) 921
• 42 Ballesteros-Tato A, León B, Graf BA. et al. Interleukin-2 inhibits germinal center formation by limiting T follicular helper cell differentiation. Immunity 2012; 36 (05) 847-856
• 43 Rana J, VanDyke D, Muñoz-Melero M. et al. An engineered Treg selective immunocytokine induces sustained immune modulation in a preclinical model of hemophilia A. J Thromb Haemost 2025; 23 (06) 1800-1809
• 44 Georgescu MT, Moorehead PC, van Velzen AS. et al. Dexamethasone promotes durable factor VIII-specific tolerance in hemophilia A mice via thymic mechanisms. Haematologica 2018; 103 (08) 1403-1413
• 45 Su RJ, Epp A, Feng J. et al. Suppression of the immune response to FVIII in hemophilia A mice by transgene modified tolerogenic dendritic cells. Mol Ther 2011; 19 (10) 1896-1904
• 46 Peng B, Ye P, Rawlings DJ, Ochs HD, Miao CH. Anti-CD3 antibodies modulate anti-factor VIII immune responses in hemophilia A mice after factor VIII plasmid-mediated gene therapy. Blood 2009; 114 (20) 4373-4382
• 47 Moghimi B, Sack BK, Nayak S, Markusic DM, Mah CS, Herzog RW. Tolerance induction to factor VIII by transient co-administration with rapamycin. J Thromb Haemost 2011; 9 (08) 1524
• 48 Qian J, Collins M, Sharpe AH, Hoyer LW. Prevention and treatment of factor VIII inhibitors in murine hemophilia A. Blood 2000; 95 (04) 1324-1329
• 49 Rana J, Perry DJ, Kumar SRP. et al. CAR- and TRuC-redirected regulatory T cells differ in capacity to control adaptive immunity to FVIII. Mol Ther 2021; 29 (09) 2660-2676
• 50 Doglio M, Rana J, Stucchi A. et al. CXCR5 engineered human and murine Tregs for targeted suppression in secondary and tertiary lymphoid organs. Front Immunol 2025; 16: 1513009